At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
Ibuprofen +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
In Brief
A Phase 2 clinical trial evaluating Ibuprofen, Placebo, and 1 other intervention for Cognitive Impairment and Malignant Neoplasm. Completed, enrolled 87 participants across 169 sites.
Detailed Summary
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Impairment, Malignant Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedJun 2017
Primary CompletionMar 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJun 14, 2017
Enrollment StartMay 26, 2017
Primary CompletionMar 30, 2022
Study CompletionJun 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.0 years ago
Interventions
Ibuprofendrug
Given PO
Placeboother
Given PO
Questionnaire Administrationother
Ancillary studies